Article
A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2021
Nakasuka Takamasa, Ohashi Kadoaki, Watanabe Hiromi, Kubo Toshio, Matsumoto Shingo, Goto Koichi, Hotta Katsuyuki, Maeda Yoshinobu, Kiura Katsuyuki
Abstract excerpt
OBJECTIVES: Pembrolizumab is a standard treatment for non-small cell lung cancer (NSCLC) with high-PD-L1 expression; however, its effect is dismal in patients with poor physical condition. Additionally, the effect of immunotherapy is generally limited in NSCLC harboring driver mutations such asEGFR, ALK, or RET gene aberrations. RESULTS: We report the beneficial effect of pembrolizumab in a patient with poor...
Topics
- Adenocarcinoma of Lung
- Antibodies, Monoclonal, Humanized
- B7-H1 Antigen
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Cytoskeletal Proteins
- Humans
- Lung Neoplasms
- Mutation